All News

Daiichi Sankyo’s US CEO and head of global oncology Ken Keller explains what his expectations are for JP Morgan prior to the conference.

The president recently announced the healthcare initiative as an effort to bring healthcare price transparency to American patients.

Graham Goodrich, CCO, Apnimed, points to 2026 as a pivotal year marked by Apnimed’s planned NDA filing for AD109, the build-out of its commercial infrastructure and access strategy, and preparations for a potential FDA decision in early 2027.

Hayley Burgess SVP, Inovalon, talks about how specialty pharmacists are evolving from dispensers into precision-care partners, using integrated data, automation, and AI to personalize therapy decisions.

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined strategy focused on sustained growth over the next decade, AbbVie highlighting continued pipeline advancements as it prepares for future revenue transitions, and Novavax detailing its shift toward a partnership-driven operating model.

A Harvard Business School (HBS) Healthcare Alumni Association Q&A with Andy Timmerwilke, Managing Director at Merrill (Bank of America).

Novavax entered the 2026 J.P. Morgan Healthcare Conference positioning itself as a partner-driven company focused on monetizing its Matrix-M platform through diversified royalties and disciplined cost control.

Strategic alignment combines data-driven intelligence with pharma and biotech commercialization to support an integrated platform for healthcare and life sciences brands.

Graham Goodrich, CCO, Apnimed, positions AD109 as a long-awaited, patient-acceptable therapy for untreated sleep apnea that delivers meaningful improvements in oxygenation, daily functioning, and peace of mind.

Company executives detailed the company’s strategy for the coming year amidst a flurry of announcements.

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen outlining how a more focused company is emerging following years of transformation, Merck detailing its strategy to de-risk long-term funding and pipeline investment, and Eli Lilly reinforcing its confidence in sustaining GLP-1-driven growth.

Genmab used the 44th Annual J.P. Morgan Healthcare Conference to reposition itself as it enters 2026 with a reshaped business model.

Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.

David Ricks detailed how the company plans to build on the success of Zepbound and Lilly Direct.

Michael O'Rourke, CEO of Re-Vana Therapeutics, touches on Re-Vana's transition from an academic spinout to a fully established biotech, marked by team expansion, facility growth, and validation of its sustained-delivery platform.

Hayley Burgess SVP, Inovalon, talks about how pharmacies preserve efficiency while strengthening patient care by using technology to unify data, streamline workflows, and proactively monitor high-risk patients across care transitions.

Bayer’s strategic portfolio refresh, late-stage pipeline progress, and operational efficiency positions the company for long-term growth across cardiovascular, oncology, and women’s health.

CEO Rob Davis details specific funding forecasts for the company beyond Keytruda.

Regeneron CEO Len Schleifer highlighted the company’s science-driven platform approach, strong 2025 commercial performance, and a robust pipeline across multiple therapeutic areas poised for regulatory filings, clinical milestones, and new product launches.

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, and continued cost discipline.

The company plans to expand its pipeline and be less reliant on a small number of blockbuster drugs.

Michael O'Rourke, CEO of Re-Vana Therapeutics, frames Re-Vana's early-stage, platform-led model as credible to public-market investors, pointing to clinical validation of sustained biologic delivery and strong collaboration interest.

Hayley Burgess SVP, Inovalon, talks about rising data fragmentation, access barriers, and adherence risks pushing specialty pharmacies to adopt integrated, end-to-end platforms that consolidate clinical, operational, and patient data.

As part of her continuing conversation with PharmExec, Trialynx CEO Angela Schwab goes into detail the importance of understanding a site’s abilities during the development stage of a trial.

In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S. investment plan, Bristol Myers Squibb outlines its long-term strategic focus at JPMorgan 2026, and Pfizer details its pivot from COVID-era products toward pipeline execution.

Pfizer entered the 44th Annual J.P. Morgan Healthcare Conference emphasizing its post-Covid reset, improved cost discipline, and a catalyst-heavy pipeline aimed at navigating the patent cycle and reaccelerating growth into 2026 and beyond.

Johnson & Johnson reinforces its long-term domestic investment strategy with a new $2 billion biologics facility in Wilson, North Carolina, further elevating the state’s role as a global life sciences hub.

CEO Christopher Boerner detailed the company’s plan to grow ahead of 2030.